Company
Headquarters: Beijing, China
Employees: 113
CEO: Dr. Zhi Hong Ph.D.
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. It develops product candidates for the treatment of chronic hepatitis B infection, human immunodeficiency virus, MDR/XDR Gram, MDR TB mycobacteria, and Covid-19 diseases; and postpartum depression and major depressive disorder diseases. The company was incorporated in 2017 and is based in Beijing, China.
Brii Biosciences Ltd has the following listings and related stock indices.
Stock: HKEX: 2137 wb_incandescent